世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

研究用抗体・試薬市場：製品（抗体（種類、形態、供給元、研究領域）、試薬）、技術（ウェスタンブロット、フローサイトメトリー、ELISA）、アプリケーション（プロテオミクス、ゲノミクス）、エンドユーザー（製薬、バイオテクノロジー、CROs）別 - 2027年までの世界予測


Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) - Global forecast to 2027

研究用抗体・試薬市場は、2022年の116億米ドルから2027年には161億米ドルに達すると予測され、予測期間中のCAGRは6.7%となります。研究用抗体・試薬市場は、プロテオミクスやゲノミクス研究の増加、研究の再現性... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年7月4日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		276 290 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

研究用抗体・試薬市場は、2022年の116億米ドルから2027年には161億米ドルに達すると予測され、予測期間中のCAGRは6.7%となります。研究用抗体・試薬市場は、プロテオミクスやゲノミクス研究の増加、研究の再現性を高めるための抗体需要の増加、ライフサイエンス業界における研究開発費の増加といった要因によって発展してきました。個別化医療や構造に基づく薬物設計の需要増に牽引されています。研究用抗体および試薬の世界市場は、今後数年間で大きな成長を遂げると予想されます。

製品別では、試薬部門が予測期間中に最も高い市場シェアを占めています。
製品ベースで、研究用抗体および試薬市場は試薬と抗体に区分されます。2021年では試薬セグメントがより大きな市場シェアを占めています。ヘルスケアや製薬分野でのバイオサイエンスやバイオテクノロジーの用途拡大などの要因が、市場を牽引しています。

on the basis oftechnology, theflow cytometrysegmentis are register the highest CAGR during the forecast period.
研究用抗体および試薬市場は、技術別にウェスタンブロッティング、フローサイトメトリー、ELISA、免疫組織化学、免疫蛍光、免疫沈降、その他の技術に区分されます。予測期間中は、フローサイトメトリー分野が最も高い成長を遂げると予想されます。この技術の利点、異種混合物内の単一細胞に対してマルチパラメーター分析を同時に行う能力、フローサイトメトリーの技術革新に伴う高い処理能力、腫瘍研究の増加などの要因が、このセグメントの成長を促進しています。


アプリケーション別では、プロテオミクスが予測期間中に最も高い市場シェアを獲得しています。
研究用抗体・試薬市場は、アプリケーションベースで、プロテオミクス、医薬品開発、ゲノミクスに区分されます。2021年には、プロテオミクスが研究用抗体および試薬の世界市場で最大のシェアを占めました。効率化のための薬物-タンパク質およびタンパク質-タンパク質相互作用のマップなどの要因。さらに、プロテオミクス技術は、薬剤の化学合成や生物学的試験に必要なコスト、時間、リソースを最小限に抑え、高い効率性を実現しています。このような要因が市場を牽引しています。

エンドユーザー別では、製薬・バイオテクノロジーが予測期間中、最も高い市場シェアを占めています。
研究用抗体・試薬市場は、製薬＆バイオテクノロジー企業、学術・研究機関、受託研究機関に分けられる。2021年の研究用抗体および試薬のエンドユーザー市場の世界シェアは、製薬＆バイオテクノロジー企業が最も高い。バイオマーカーの同定や定量化など、医薬品開発における研究用抗体の利用が拡大していることなどが、市場を牽引しています。


地域別では、アジア太平洋地域が予測期間中に最も高いCAGRを記録すると予想されています。

予測期間中（2022年～2027年）、アジア太平洋地域の研究用抗体・試薬市場は最も高いCAGRで成長すると予測されます。プロテオミクスやゲノミクスの研究の増加や研究資金の増加、製薬会社やバイオテクノロジー企業による投資、同地域の認知度の高まりなどの要因が、同地域の市場を牽引しています。

主な参加企業の内訳は、以下の通り。
- 企業タイプ別 - Tier 1-35%、Tier 2-45%、Tier 3-20
- 役職別：Cレベル-35%、ディレクターレベル-25%、その他-40
- 地域別：北米-45%、欧州-30%、アジア太平洋-20%、中南米-3%、中東・アフリカ-2

研究用抗体および試薬市場の主要企業

研究用抗体および試薬システムで事業を展開している主な企業は、Thermo Fisher Scientific, Inc.米国）、Merck KGaA（ドイツ）、Abcam plc.(米国）、Becton, Dickinson and Company（米国）、Bio-Rad Laboratories（米国）、Cell Signaling Technology（米国）、F. Hoffmann-La Roche（スイス）、Danaher Corporation（米国）、Agilent Technologies（米国）、PerkinElmer（米国）、Lonza（スイス）、GenScript（中国）、および BioLegend（米国）です。

調査対象

このレポートでは、研究用抗体および試薬の市場を分析し、製品、流通チャネル、地域などのさまざまなセグメントに基づいて市場規模および今後の成長可能性を推定することを目的としています。また、市場で入手可能な様々な研究用抗体および試薬製品の製品ポートフォリオマトリックスも掲載しています。また、この市場の主要企業の競争力分析、企業プロファイル、製品提供、主要な市場戦略も掲載しています。
本レポートを購入する理由
このレポートは、市場のより重要なシェアを獲得し、順番にhelpthemだろう、市場のパルスを測定するために確立された企業だけでなく、新規参入者/中小企業を豊かにする。レポートを購入する企業は、1つまたは以下の戦略の任意の組み合わせを使用して、市場での地位をtostrengthen可能性があります。

このレポートでは、次のポインタへの洞察を提供します。
- 市場の浸透。市場の浸透：世界の研究用抗体および試薬市場のトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場を製品別、流通チャネル別に分析しています。
- 製品の強化/革新。世界の研究用抗体および試薬市場における今後の動向と製品の発売に関する詳細な洞察。
- 市場開発。製品別、流通チャネル別に有望な新興市場に関する包括的な情報を提供します。
- 市場の多様化。世界の研究用抗体および試薬市場における新製品や製品の強化、成長地域、最近の開発、投資に関する徹底的な情報。
- 競争力の評価。世界の研究用抗体および試薬市場における主要企業の市場占有率、成長戦略、製品提供、競争上のリーダーシップマッピング、能力に関する詳細な評価。

ページTOPに戻る


目次

1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.2.2 MARKETS COVERED 35
FIGURE 1 GLOBAL RESEARCH ANTIBODIES AND REAGENTS MARKET 35
FIGURE 2 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SCOPE 36
1.2.3 YEARS CONSIDERED FOR THE STUDY 36
1.3 CURRENCY 37
1.4 STAKEHOLDERS 37
1.5 LIMITATIONS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH APPROACH 38
FIGURE 3 RESEARCH DESIGN 38
2.1.1 SECONDARY RESEARCH 39
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY RESEARCH 40
FIGURE 4 PRIMARY SOURCES 40
2.1.2.1 Key data from primary sources 41
2.1.2.2 Breakdown of primaries 41
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 42
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 7 MARKET SIZING FROM COMPANY REVENUE 43
FIGURE 8 MARKET ANALYSIS APPROACH 44
FIGURE 9 TOP-DOWN APPROACH 44
2.3 DATA TRIANGULATION APPROACH 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.4 MARKET SHARE ESTIMATION 47
2.5 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 48
FIGURE 12 RESEARCH ANTIBODIES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 49
FIGURE 13 RESEARCH REAGENTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 49
FIGURE 14 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 50
FIGURE 15 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 50
FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 51
FIGURE 17 GEOGRAPHIC ANALYSIS: RESEARCH ANTIBODIES AND REAGENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 RESEARCH ANTIBODIES AND REAGENTS: MARKET OVERVIEW 53
FIGURE 18 INCREASING R&D EXPENDITURE IN THE LIFE SCIENCE INDUSTRY TO DRIVE MARKET GROWTH 53
4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 54
FIGURE 19 PROTEOMICS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC RESEARCH ANTIBODIES AND REAGENTS MARKET IN 2021 54
4.3 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 CHINA SHOWS THE HIGHEST REVENUE GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD 55
4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 56
FIGURE 21 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RESEARCH ANTIBODIES AND REAGENTS MARKET UNTIL 2027 56
4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEVELOPED VS. DEVELOPING MARKETS 56
FIGURE 22 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE IN THE FORECAST PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 23 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 57
5.2.1 DRIVERS 58
5.2.1.1 Increasing research activity and funding for R&D 58
5.2.1.2 Growing industry-academia collaboration 58
TABLE 1 KEY MARKET DRIVERS: IMPACT ANALYSIS 59
5.2.2 RESTRAINTS 59
5.2.2.1 Quality concerns and a lack of reproducible results 59
TABLE 2 KEY MARKET RESTRAINTS: IMPACT ANALYSIS 59
 
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emerging markets 60
5.2.3.2 Personalized medicine and protein therapeutics 60
5.2.3.3 Growth in stem cell and neurobiology research 61
5.2.3.4 Increasing focus on biomarker discovery 61
5.2.3.5 Rising interest in outsourcing 62
TABLE 3 KEY MARKET OPPORTUNITIES: IMPACT ANALYSIS 62
5.2.4 CHALLENGES 62
5.2.4.1 Cost and time-intensive antibody development processes 62
5.2.4.2 Pricing pressure faced by prominent market players 63
TABLE 4 KEY MARKET CHALLENGES: IMPACT ANALYSIS 63
5.3 INDUSTRY TRENDS 63
5.3.1 INCREASING RESEARCH ON THERAPEUTIC ANTIBODIES 64
5.3.2 RECOMBINANT ANTIBODIES SUPPORTING THE SMOOTH TRANSITION FROM IN VITRO TO IN VIVO 64
5.3.3 GROWING CONSOLIDATION OF THE LIFE SCIENCES MARKET FOR ANTIBODIES AND REAGENTS 65
TABLE 5 MAJOR ACQUISITIONS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET 65
5.4 STAKEHOLDER ANALYSIS 65
FIGURE 24 RESEARCH ANTIBODIES AND REAGENTS MARKETS: STAKEHOLDER ANALYSIS (2021) 67
5.5 STRATEGIC BENCHMARKING 67
TABLE 6 PRODUCT PORTFOLIO ANALYSIS 68
5.6 IMPACT OF COVID-19 ON THE RESEARCH ANTIBODIES AND REAGENTS MARKET 68
5.7 SUPPLY CHAIN ANALYSIS 69
FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: SUPPLY CHAIN ANALYSIS 70
5.8 TECHNOLOGY ANALYSIS 70
5.9 REGULATORY ANALYSIS 72
5.10 PORTER’S FIVE FORCES 72
TABLE 7 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 72
5.10.1 THREAT OF NEW ENTRANTS 73
5.10.2 THREAT OF SUBSTITUTES 73
5.10.3 BARGAINING POWER OF SUPPLIERS 73
5.10.4 BARGAINING POWER OF BUYERS 73
5.10.5 DEGREE OF COMPETITION 73
5.11 PRICING ANALYSIS 74
TABLE 8 SELLING PRICE OF HPAPI PRODUCTS BY TOP PLAYERS 74
 
6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT 75
6.1 INTRODUCTION 76
TABLE 9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 76
6.2 REAGENTS 76
TABLE 10 REAGENTS, BY TYPE 77
TABLE 11 RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 12 RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
6.2.1 MEDIA & SERA 79
6.2.1.1 Media & sera hold the largest share of the reagents market 79
TABLE 13 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2020–2027 (USD MILLION) 80
6.2.2 STAINS & DYES 80
6.2.2.1 The growth of the life sciences industry is driving the demand and use of stains & dyes 80
TABLE 14 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.2.3 FIXATIVES 82
6.2.3.1 Fixative agents are needed to preserve the morphology and antigenicity of target molecules 82
TABLE 15 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.2.4 BUFFERS 83
6.2.4.1 Wide use in drug development will drive the market for buffers 83
TABLE 16 RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2020–2027 (USD MILLION) 83
6.2.5 SOLVENTS 84
6.2.5.1 Organic solvents see wide use in pharmaceutical processes and assays like IHC 84
TABLE 17 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.2.6 ENZYMES 85
6.2.6.1 An increase in proteomic and genomic research activity will ensure the demand for enzymes 85
TABLE 18 RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2020–2027 (USD MILLION) 85
6.2.7 PROBES 86
6.2.7.1 The versatility, sensitivity, and quantitative capabilities of probes have ensured their use in research 86
TABLE 19 RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.2.8 OTHER REAGENTS 87
TABLE 20 OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
6.3 ANTIBODIES 88
TABLE 21 RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
6.3.1 ANTIBODIES, BY TYPE 89
TABLE 22 ANTIBODIES, BY TYPE 89
TABLE 23 RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
6.3.1.1 Primary antibodies 90
6.3.1.1.1 Rising R&D activity and expenditure driving the demand for accurate and reliable antibodies 90
TABLE 24 PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
6.3.1.2 Secondary antibodies 91
6.3.1.2.1 Versatility and low cost of production have ensured stable growth in the market for secondary antibodies 91
TABLE 25 SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
6.3.2 ANTIBODIES, BY FORM 92
TABLE 26 ANTIBODIES, BY FORM 93
TABLE 27 RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 93
6.3.2.1 Monoclonal antibodies 94
6.3.2.1.1 Monoclonal antibodies are among the most common tools in biomedical science 94
TABLE 28 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
6.3.2.2 Polyclonal antibodies 95
6.3.2.2.1 Thermo Fisher Scientific and Abcam are major players in the polyclonal antibodies market 95
TABLE 29 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
6.3.2.3 Recombinant antibodies 96
6.3.2.3.1 Recombinant antibodies provide a highly specific & sensitive option for cancer treatment 96
TABLE 30 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96
6.3.3 ANTIBODIES, BY SOURCE 96
TABLE 31 ANTIBODIES, BY SOURCE 97
TABLE 32 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 98
6.3.3.1 Mice 98
6.3.3.1.1 Mice are the preferred hosts for research-use antibody production 98
TABLE 33 MOUSE ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
6.3.3.2 Rabbits 99
6.3.3.2.1 Rabbits are a cost-effective means of antibody production 99
TABLE 34 RABBIT ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
6.3.3.3 Other sources 100
TABLE 35 OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 101
6.3.4 ANTIBODIES, BY RESEARCH AREA 101
TABLE 36 ANTIBODIES, BY RESEARCH AREA 101
TABLE 37 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 103
6.3.4.1 Oncology 103
6.3.4.1.1 High prevalence of cancer has boosted oncology research 103
TABLE 38 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 104
6.3.4.2 Infectious diseases 104
6.3.4.2.1 Rising awareness and growing research activity are key drivers of the market 104
TABLE 39 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.3.4.3 Immunology 105
6.3.4.3.1 Antibodies are used to identify protein and peptides to understand infectious disease immunology better 105
TABLE 40 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.3.4.4 Neurobiology 106
6.3.4.4.1 Antibody-based approaches are widely used in molecular and cellular neuroscience 106
TABLE 41 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 107
6.3.4.5 Stem cells 107
6.3.4.5.1 Increasing funding and the growing importance of stem cells in transplantation are key market drivers 107
TABLE 42 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 108
6.3.4.6 Other research areas 109
TABLE 43 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 110
7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY 111
7.1 INTRODUCTION 112
TABLE 44 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
7.2 WESTERN BLOTTING 112
7.2.1 HIGH ACCURACY, EASE OF INTERPRETATION, AND OTHER ADVANTAGES HAVE PROPELLED THE USE OF WESTERN BLOTTING 112
TABLE 45 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2020–2027 (USD MILLION) 113
7.3 FLOW CYTOMETRY 114
7.3.1 FLOW CYTOMETRY IS THE FASTEST-GROWING TECHNOLOGY SEGMENT OF THE MARKET 114
TABLE 46 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION) 115
7.4 ENZYME-LINKED IMMUNOSORBENT ASSAY 115
7.4.1 ELISA HAS THE POTENTIAL TO SUPERSEDE THE CURRENT GOLD STANDARD FOR COVID-19 TESTING 115
TABLE 47 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION) 116
7.5 IMMUNOHISTOCHEMISTRY 117
7.5.1 COMPLEXITIES OF IHC POSE CHALLENGES TO MARKET GROWTH 117
TABLE 48 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020–2027 (USD MILLION) 118
7.6 IMMUNOFLUORESCENCE 118
7.6.1 IMMUNOFLUORESCENCE HELPS DETERMINE SPECIFIC GENE EXPRESSIONS 118
TABLE 49 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2020–2027 (USD MILLION) 119
7.7 IMMUNOPRECIPITATION 120
7.7.1 RESULTS OBTAINED BY IP CAN BE ANALYZED THROUGH OTHER TECHNOLOGIES 120
TABLE 50 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2020–2027 (USD MILLION) 121
7.8 OTHER TECHNOLOGIES 121
TABLE 51 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 122
8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 123
8.1 INTRODUCTION 124
TABLE 52 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
8.2 PROTEOMICS 124
8.2.1 PROTEOMICS HOLDS THE LARGEST SHARE OF THE MARKET, BY APPLICATION 124
TABLE 53 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS 125
TABLE 54 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2020–2027 (USD MILLION) 126
8.3 DRUG DEVELOPMENT 126
8.3.1 THE DRUG DEVELOPMENT APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST RATE 126
FIGURE 26 APPLICATION OF ANTIBODIES IN THE DRUG DEVELOPMENT PROCESS 127
TABLE 55 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 128
8.4 GENOMICS 128
8.4.1 GENOMICS IS AN EMERGING AREA OF RESEARCH APPLICATIONS EXPECTED TO SEE GROWTH IN THE COMING YEARS 128
TABLE 56 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2020–2027 (USD MILLION) 129
9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER 130
9.1 INTRODUCTION 131
TABLE 57 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 131
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 131
9.2.1 PHARMA & BIOTECH COMPANIES DOMINATE THE END-USER MARKET 131
TABLE 58 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 132
9.3 ACADEMIC & RESEARCH INSTITUTIONS 132
9.3.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL THE MARKET 132
TABLE 59 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
9.4 CONTRACT RESEARCH ORGANIZATIONS 134
9.4.1 GROWING CONTRACT RESEARCH ON MONOCLONAL ANTIBODIES AND DRUG CONJUGATES AIDS MARKET GROWTH 134
TABLE 60 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 134
10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 135
10.1 INTRODUCTION 136
FIGURE 27 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SNAPSHOT (2021) 136
TABLE 61 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 137
10.2 NORTH AMERICA 137
FIGURE 28 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 138
TABLE 62 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 63 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 139
TABLE 64 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 65 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 66 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 140
TABLE 67 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 140
TABLE 68 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 140
TABLE 69 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 141
TABLE 70 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 141
TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 141
10.2.1 US 142
10.2.1.1 The US dominates the North American market in terms of market share 142
TABLE 72 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION) 142
TABLE 73 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 143
TABLE 74 US: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 75 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 76 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 144
TABLE 77 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 144
TABLE 78 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 144
TABLE 79 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 145
TABLE 80 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 81 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 145
10.2.2 CANADA 146
10.2.2.1 Rising cancer incidence and a favorable funding scenario will push market growth in Canada 146
TABLE 82 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 147
TABLE 83 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 84 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 85 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 148
TABLE 86 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 148
TABLE 87 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 148
TABLE 88 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 149
TABLE 89 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 149
TABLE 90 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 149
10.3 EUROPE 150
TABLE 91 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 92 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 150
TABLE 93 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 94 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 95 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 151
TABLE 96 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 152
TABLE 97 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 152
TABLE 98 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 152
TABLE 99 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 100 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 153
10.3.1 GERMANY 153
10.3.1.1 Germany holds the largest share of the market in Europe 153
TABLE 101 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 154
TABLE 102 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 103 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 104 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 155
TABLE 105 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 155
TABLE 106 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 155
TABLE 107 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 156
TABLE 108 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 156
TABLE 109 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 156
10.3.2 UK 157
10.3.2.1 The market in the UK is characterized by expansions by leading players and growing R&D investments 157
TABLE 110 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 157
TABLE 111 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 112 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 113 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 158
TABLE 114 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 159
TABLE 115 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 159
TABLE 116 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 159
TABLE 117 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 118 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 160
 
10.3.3 FRANCE 160
10.3.3.1 Rising infrastructural development and research activity support market growth in France 160
TABLE 119 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 161
TABLE 120 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 121 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 122 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 162
TABLE 123 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 162
TABLE 124 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 162
TABLE 125 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 163
TABLE 126 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 163
TABLE 127 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 163
10.3.4 ITALY 164
10.3.4.1 Increasing R&D in life sciences and favorable funding are key drivers of the Italian market 164
TABLE 128 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 164
TABLE 129 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 130 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 131 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 165
TABLE 132 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 166
TABLE 133 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 166
TABLE 134 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 166
TABLE 135 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167
TABLE 136 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.3.5 SPAIN 167
10.3.5.1 A favorable scenario for research initiatives drives the market in Spain 167
TABLE 137 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 168
TABLE 138 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 139 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 140 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 169
TABLE 141 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 169
TABLE 142 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 169
TABLE 143 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 170
TABLE 144 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170
TABLE 145 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
10.3.6 REST OF EUROPE 171
TABLE 146 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 171
TABLE 147 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 148 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 149 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 172
TABLE 150 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 173
TABLE 151 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 173
TABLE 152 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 173
TABLE 153 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 174
TABLE 154 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 174
10.4 ASIA PACIFIC 174
FIGURE 29 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 175
TABLE 155 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 156 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 176
TABLE 157 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 158 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 177
TABLE 160 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 177
TABLE 161 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 178
TABLE 162 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 178
TABLE 163 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 178
TABLE 164 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 179
10.4.1 JAPAN 179
10.4.1.1 Japan dominates the Asia Pacific market 179
TABLE 165 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 180
TABLE 166 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 167 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 168 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 181
TABLE 169 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 181
TABLE 170 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 181
TABLE 171 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182
TABLE 172 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 182
TABLE 173 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 182
10.4.2 CHINA 183
10.4.2.1 China is the fastest-growing segment of the overall market 183
TABLE 174 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 184
TABLE 175 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 176 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 177 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 185
TABLE 178 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 185
TABLE 179 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 185
TABLE 180 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 186
TABLE 181 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 186
TABLE 182 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 186
10.4.3 INDIA 187
10.4.3.1 Strong economic growth and rising demand for pharmaceuticals are key market drivers in India 187
TABLE 183 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 184 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 185 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 186 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 188
TABLE 187 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 189
TABLE 188 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 189
TABLE 189 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 189
TABLE 190 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190
TABLE 191 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 190
10.4.4 REST OF ASIA PACIFIC 190
TABLE 192 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 191
TABLE 193 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 194 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 195 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 192
TABLE 196 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 192
TABLE 197 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 193
TABLE 198 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 193
TABLE 199 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 193
TABLE 200 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 194
10.5 LATIN AMERICA 194
10.5.1 BRAZIL AND MEXICO TO GROW AT HIGH RATES IN THE LATAM MARKET 194
TABLE 201 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 195
TABLE 202 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 204 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 196
TABLE 205 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 196
TABLE 206 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 196
TABLE 207 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 197
TABLE 208 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 197
TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 197
10.6 MIDDLE EAST AND AFRICA 198
10.6.1 MEA HOLDS THE SMALLEST SHARE OF THE MARKET BUT IS EXPECTED TO PROVIDE STRONG GROWTH OPPORTUNITIES 198
TABLE 210 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 198
TABLE 211 MEA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 212 MEA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 213 MEA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 199
TABLE 214 MEA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 200
TABLE 215 MEA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 200
TABLE 216 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 200
TABLE 217 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 201
TABLE 218 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 201
11 COMPETITIVE LANDSCAPE 202
11.1 OVERVIEW 202
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 203
FIGURE 30 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET 203
11.3 RESEARCH ANTIBODIES MARKET SHARE ANALYSIS 204
FIGURE 31 GLOBAL RESEARCH ANTIBODIES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 204
11.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 206
FIGURE 32 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET, 2019–2021 206
11.5 COMPANY EVALUATION QUADRANT 206
11.5.1 STARS 206
11.5.2 EMERGING LEADERS 206
11.5.3 PERVASIVE PLAYERS 207
11.5.4 PARTICIPANTS 207
FIGURE 33 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT, 2021 207
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 208
11.6.1 PROGRESSIVE COMPANIES 208
11.6.2 STARTING BLOCKS 208
11.6.3 RESPONSIVE COMPANIES 208
11.6.4 DYNAMIC COMPANIES 208
FIGURE 34 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021 209
11.7 COMPANY FOOTPRINT ANALYSIS 210
11.7.1 COMPANY PRODUCT FOOTPRINT 210
TABLE 219 COMPANY PRODUCT FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021) 210
11.7.2 COMPANY REGIONAL FOOTPRINT 211
TABLE 220 COMPANY REGIONAL FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021) 211
11.8 COMPETITIVE SITUATION AND TRENDS 212
TABLE 221 PRODUCT LAUNCHES 212
TABLE 222 DEALS 212
TABLE 223 OTHER DEVELOPMENTS 213

　

ページTOPに戻る


　

Summary

The research antibodies and reagents market is projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market evolved owing to factors such as increasing proteomics and genomics research, growing demand for antibodies for research reproducibility, and increasing R&D expenditure in the life sciences industry. Driven by the increasing demand for personalized medicine and structure-based drug design. It is expected that the global research antibodies and reagentsmarket will witness significant growth in the coming years.

On the basis ofproduct, the reagentssegment holds the highest market share during the forecast period.
On the basis of product, the research antibodies and reagents market are segmented into reagent and antibodies. In 2021the reagent segment accounted for the larger market share. Factors such as increasing applications of biosciences and biotechnology within the healthcare and pharmaceutical fields is driving the market.

On the basis oftechnology, theflow cytometrysegmentis expected to register the highest CAGR during the forecast period.
On the basis of technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. During the forecast period the flow cytometry segment is expected to witness the highest growth. Factors such as advantages of this technique, its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture, offering high throughput along with technological innovations in flow cytometry and increasingoncology research, are driving the growth of this segment.


On the basis ofapplication, the proteomicsholds the highest market share during the forecast period.
On the basis of application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. In 2021, Proteomics held the largest share of the global research antibodies and reagents market. Factors such as increasing efficiency maps drug-protein and protein-protein interactions. Additionally, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs and are highly efficient. Such factors are driving the market.

On the basis of enduser, the pharmaceutical & biotechnology holds the highest market share during the forecast period.
The research antibodies and reagents market is divided into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. In 2021the pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market. Factors such as growing use of research antibodies in drug development for the identification and quantification of biomarkers and other techniques are driving the market.


By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

During the forecast period (2022 to 2027), the Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR. Factors such as increasing research in proteomics and genomics and growing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness in the region are driving the market in the region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45% and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, AsiaPacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the research antibodies and reagentsmarket

The key players operating in the research antibodies and reagents systems includeThermo Fisher Scientific, Inc. US), Merck KGaA (Germany), Abcam plc. (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Research Coverage:

The report analyzes the research antibodies and reagent marketand aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, andregion. The report also includes aproduct portfolio matrix of various research antibodies and reagents productsavailable in the market. The report also providesa competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would helpthem, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies tostrengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global research antibodies and reagentmarket. The report analyzes this marketby product and distribution channel.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and productlaunches in the globalresearch antibodies and reagentmarket.
• Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in theglobal research antibodies and reagent market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in theglobal research antibodies and reagent market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.2.2 MARKETS COVERED 35
FIGURE 1 GLOBAL RESEARCH ANTIBODIES AND REAGENTS MARKET 35
FIGURE 2 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SCOPE 36
1.2.3 YEARS CONSIDERED FOR THE STUDY 36
1.3 CURRENCY 37
1.4 STAKEHOLDERS 37
1.5 LIMITATIONS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH APPROACH 38
FIGURE 3 RESEARCH DESIGN 38
2.1.1 SECONDARY RESEARCH 39
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY RESEARCH 40
FIGURE 4 PRIMARY SOURCES 40
2.1.2.1 Key data from primary sources 41
2.1.2.2 Breakdown of primaries 41
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 42
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 7 MARKET SIZING FROM COMPANY REVENUE 43
FIGURE 8 MARKET ANALYSIS APPROACH 44
FIGURE 9 TOP-DOWN APPROACH 44
2.3 DATA TRIANGULATION APPROACH 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.4 MARKET SHARE ESTIMATION 47
2.5 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 48
FIGURE 12 RESEARCH ANTIBODIES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 49
FIGURE 13 RESEARCH REAGENTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 49
FIGURE 14 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 50
FIGURE 15 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 50
FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 51
FIGURE 17 GEOGRAPHIC ANALYSIS: RESEARCH ANTIBODIES AND REAGENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 RESEARCH ANTIBODIES AND REAGENTS: MARKET OVERVIEW 53
FIGURE 18 INCREASING R&D EXPENDITURE IN THE LIFE SCIENCE INDUSTRY TO DRIVE MARKET GROWTH 53
4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 54
FIGURE 19 PROTEOMICS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC RESEARCH ANTIBODIES AND REAGENTS MARKET IN 2021 54
4.3 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 CHINA SHOWS THE HIGHEST REVENUE GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD 55
4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 56
FIGURE 21 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RESEARCH ANTIBODIES AND REAGENTS MARKET UNTIL 2027 56
4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEVELOPED VS. DEVELOPING MARKETS 56
FIGURE 22 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE IN THE FORECAST PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 23 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 57
5.2.1 DRIVERS 58
5.2.1.1 Increasing research activity and funding for R&D 58
5.2.1.2 Growing industry-academia collaboration 58
TABLE 1 KEY MARKET DRIVERS: IMPACT ANALYSIS 59
5.2.2 RESTRAINTS 59
5.2.2.1 Quality concerns and a lack of reproducible results 59
TABLE 2 KEY MARKET RESTRAINTS: IMPACT ANALYSIS 59
 
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emerging markets 60
5.2.3.2 Personalized medicine and protein therapeutics 60
5.2.3.3 Growth in stem cell and neurobiology research 61
5.2.3.4 Increasing focus on biomarker discovery 61
5.2.3.5 Rising interest in outsourcing 62
TABLE 3 KEY MARKET OPPORTUNITIES: IMPACT ANALYSIS 62
5.2.4 CHALLENGES 62
5.2.4.1 Cost and time-intensive antibody development processes 62
5.2.4.2 Pricing pressure faced by prominent market players 63
TABLE 4 KEY MARKET CHALLENGES: IMPACT ANALYSIS 63
5.3 INDUSTRY TRENDS 63
5.3.1 INCREASING RESEARCH ON THERAPEUTIC ANTIBODIES 64
5.3.2 RECOMBINANT ANTIBODIES SUPPORTING THE SMOOTH TRANSITION FROM IN VITRO TO IN VIVO 64
5.3.3 GROWING CONSOLIDATION OF THE LIFE SCIENCES MARKET FOR ANTIBODIES AND REAGENTS 65
TABLE 5 MAJOR ACQUISITIONS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET 65
5.4 STAKEHOLDER ANALYSIS 65
FIGURE 24 RESEARCH ANTIBODIES AND REAGENTS MARKETS: STAKEHOLDER ANALYSIS (2021) 67
5.5 STRATEGIC BENCHMARKING 67
TABLE 6 PRODUCT PORTFOLIO ANALYSIS 68
5.6 IMPACT OF COVID-19 ON THE RESEARCH ANTIBODIES AND REAGENTS MARKET 68
5.7 SUPPLY CHAIN ANALYSIS 69
FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: SUPPLY CHAIN ANALYSIS 70
5.8 TECHNOLOGY ANALYSIS 70
5.9 REGULATORY ANALYSIS 72
5.10 PORTER’S FIVE FORCES 72
TABLE 7 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 72
5.10.1 THREAT OF NEW ENTRANTS 73
5.10.2 THREAT OF SUBSTITUTES 73
5.10.3 BARGAINING POWER OF SUPPLIERS 73
5.10.4 BARGAINING POWER OF BUYERS 73
5.10.5 DEGREE OF COMPETITION 73
5.11 PRICING ANALYSIS 74
TABLE 8 SELLING PRICE OF HPAPI PRODUCTS BY TOP PLAYERS 74
 
6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT 75
6.1 INTRODUCTION 76
TABLE 9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 76
6.2 REAGENTS 76
TABLE 10 REAGENTS, BY TYPE 77
TABLE 11 RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 12 RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
6.2.1 MEDIA & SERA 79
6.2.1.1 Media & sera hold the largest share of the reagents market 79
TABLE 13 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2020–2027 (USD MILLION) 80
6.2.2 STAINS & DYES 80
6.2.2.1 The growth of the life sciences industry is driving the demand and use of stains & dyes 80
TABLE 14 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.2.3 FIXATIVES 82
6.2.3.1 Fixative agents are needed to preserve the morphology and antigenicity of target molecules 82
TABLE 15 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.2.4 BUFFERS 83
6.2.4.1 Wide use in drug development will drive the market for buffers 83
TABLE 16 RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2020–2027 (USD MILLION) 83
6.2.5 SOLVENTS 84
6.2.5.1 Organic solvents see wide use in pharmaceutical processes and assays like IHC 84
TABLE 17 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.2.6 ENZYMES 85
6.2.6.1 An increase in proteomic and genomic research activity will ensure the demand for enzymes 85
TABLE 18 RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2020–2027 (USD MILLION) 85
6.2.7 PROBES 86
6.2.7.1 The versatility, sensitivity, and quantitative capabilities of probes have ensured their use in research 86
TABLE 19 RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.2.8 OTHER REAGENTS 87
TABLE 20 OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
6.3 ANTIBODIES 88
TABLE 21 RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
6.3.1 ANTIBODIES, BY TYPE 89
TABLE 22 ANTIBODIES, BY TYPE 89
TABLE 23 RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
6.3.1.1 Primary antibodies 90
6.3.1.1.1 Rising R&D activity and expenditure driving the demand for accurate and reliable antibodies 90
TABLE 24 PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
6.3.1.2 Secondary antibodies 91
6.3.1.2.1 Versatility and low cost of production have ensured stable growth in the market for secondary antibodies 91
TABLE 25 SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
6.3.2 ANTIBODIES, BY FORM 92
TABLE 26 ANTIBODIES, BY FORM 93
TABLE 27 RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 93
6.3.2.1 Monoclonal antibodies 94
6.3.2.1.1 Monoclonal antibodies are among the most common tools in biomedical science 94
TABLE 28 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
6.3.2.2 Polyclonal antibodies 95
6.3.2.2.1 Thermo Fisher Scientific and Abcam are major players in the polyclonal antibodies market 95
TABLE 29 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
6.3.2.3 Recombinant antibodies 96
6.3.2.3.1 Recombinant antibodies provide a highly specific & sensitive option for cancer treatment 96
TABLE 30 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96
6.3.3 ANTIBODIES, BY SOURCE 96
TABLE 31 ANTIBODIES, BY SOURCE 97
TABLE 32 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 98
6.3.3.1 Mice 98
6.3.3.1.1 Mice are the preferred hosts for research-use antibody production 98
TABLE 33 MOUSE ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
6.3.3.2 Rabbits 99
6.3.3.2.1 Rabbits are a cost-effective means of antibody production 99
TABLE 34 RABBIT ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
6.3.3.3 Other sources 100
TABLE 35 OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 101
6.3.4 ANTIBODIES, BY RESEARCH AREA 101
TABLE 36 ANTIBODIES, BY RESEARCH AREA 101
TABLE 37 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 103
6.3.4.1 Oncology 103
6.3.4.1.1 High prevalence of cancer has boosted oncology research 103
TABLE 38 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 104
6.3.4.2 Infectious diseases 104
6.3.4.2.1 Rising awareness and growing research activity are key drivers of the market 104
TABLE 39 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.3.4.3 Immunology 105
6.3.4.3.1 Antibodies are used to identify protein and peptides to understand infectious disease immunology better 105
TABLE 40 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.3.4.4 Neurobiology 106
6.3.4.4.1 Antibody-based approaches are widely used in molecular and cellular neuroscience 106
TABLE 41 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 107
6.3.4.5 Stem cells 107
6.3.4.5.1 Increasing funding and the growing importance of stem cells in transplantation are key market drivers 107
TABLE 42 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION) 108
6.3.4.6 Other research areas 109
TABLE 43 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 110
7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY 111
7.1 INTRODUCTION 112
TABLE 44 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
7.2 WESTERN BLOTTING 112
7.2.1 HIGH ACCURACY, EASE OF INTERPRETATION, AND OTHER ADVANTAGES HAVE PROPELLED THE USE OF WESTERN BLOTTING 112
TABLE 45 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2020–2027 (USD MILLION) 113
7.3 FLOW CYTOMETRY 114
7.3.1 FLOW CYTOMETRY IS THE FASTEST-GROWING TECHNOLOGY SEGMENT OF THE MARKET 114
TABLE 46 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION) 115
7.4 ENZYME-LINKED IMMUNOSORBENT ASSAY 115
7.4.1 ELISA HAS THE POTENTIAL TO SUPERSEDE THE CURRENT GOLD STANDARD FOR COVID-19 TESTING 115
TABLE 47 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION) 116
7.5 IMMUNOHISTOCHEMISTRY 117
7.5.1 COMPLEXITIES OF IHC POSE CHALLENGES TO MARKET GROWTH 117
TABLE 48 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020–2027 (USD MILLION) 118
7.6 IMMUNOFLUORESCENCE 118
7.6.1 IMMUNOFLUORESCENCE HELPS DETERMINE SPECIFIC GENE EXPRESSIONS 118
TABLE 49 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2020–2027 (USD MILLION) 119
7.7 IMMUNOPRECIPITATION 120
7.7.1 RESULTS OBTAINED BY IP CAN BE ANALYZED THROUGH OTHER TECHNOLOGIES 120
TABLE 50 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2020–2027 (USD MILLION) 121
7.8 OTHER TECHNOLOGIES 121
TABLE 51 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 122
8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 123
8.1 INTRODUCTION 124
TABLE 52 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
8.2 PROTEOMICS 124
8.2.1 PROTEOMICS HOLDS THE LARGEST SHARE OF THE MARKET, BY APPLICATION 124
TABLE 53 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS 125
TABLE 54 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2020–2027 (USD MILLION) 126
8.3 DRUG DEVELOPMENT 126
8.3.1 THE DRUG DEVELOPMENT APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST RATE 126
FIGURE 26 APPLICATION OF ANTIBODIES IN THE DRUG DEVELOPMENT PROCESS 127
TABLE 55 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 128
8.4 GENOMICS 128
8.4.1 GENOMICS IS AN EMERGING AREA OF RESEARCH APPLICATIONS EXPECTED TO SEE GROWTH IN THE COMING YEARS 128
TABLE 56 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2020–2027 (USD MILLION) 129
9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER 130
9.1 INTRODUCTION 131
TABLE 57 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 131
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 131
9.2.1 PHARMA & BIOTECH COMPANIES DOMINATE THE END-USER MARKET 131
TABLE 58 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 132
9.3 ACADEMIC & RESEARCH INSTITUTIONS 132
9.3.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL THE MARKET 132
TABLE 59 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
9.4 CONTRACT RESEARCH ORGANIZATIONS 134
9.4.1 GROWING CONTRACT RESEARCH ON MONOCLONAL ANTIBODIES AND DRUG CONJUGATES AIDS MARKET GROWTH 134
TABLE 60 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 134
10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 135
10.1 INTRODUCTION 136
FIGURE 27 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SNAPSHOT (2021) 136
TABLE 61 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 137
10.2 NORTH AMERICA 137
FIGURE 28 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 138
TABLE 62 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 63 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 139
TABLE 64 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 65 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 66 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 140
TABLE 67 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 140
TABLE 68 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 140
TABLE 69 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 141
TABLE 70 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 141
TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 141
10.2.1 US 142
10.2.1.1 The US dominates the North American market in terms of market share 142
TABLE 72 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION) 142
TABLE 73 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 143
TABLE 74 US: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 75 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 76 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 144
TABLE 77 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 144
TABLE 78 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 144
TABLE 79 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 145
TABLE 80 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 81 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 145
10.2.2 CANADA 146
10.2.2.1 Rising cancer incidence and a favorable funding scenario will push market growth in Canada 146
TABLE 82 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 147
TABLE 83 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 84 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 85 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 148
TABLE 86 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 148
TABLE 87 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 148
TABLE 88 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 149
TABLE 89 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 149
TABLE 90 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 149
10.3 EUROPE 150
TABLE 91 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 92 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 150
TABLE 93 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 94 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 95 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 151
TABLE 96 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 152
TABLE 97 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 152
TABLE 98 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 152
TABLE 99 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 100 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 153
10.3.1 GERMANY 153
10.3.1.1 Germany holds the largest share of the market in Europe 153
TABLE 101 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 154
TABLE 102 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 103 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 104 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 155
TABLE 105 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 155
TABLE 106 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 155
TABLE 107 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 156
TABLE 108 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 156
TABLE 109 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 156
10.3.2 UK 157
10.3.2.1 The market in the UK is characterized by expansions by leading players and growing R&D investments 157
TABLE 110 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 157
TABLE 111 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 112 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 113 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 158
TABLE 114 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 159
TABLE 115 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 159
TABLE 116 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 159
TABLE 117 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 118 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 160
 
10.3.3 FRANCE 160
10.3.3.1 Rising infrastructural development and research activity support market growth in France 160
TABLE 119 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 161
TABLE 120 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 121 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 122 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 162
TABLE 123 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 162
TABLE 124 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 162
TABLE 125 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 163
TABLE 126 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 163
TABLE 127 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 163
10.3.4 ITALY 164
10.3.4.1 Increasing R&D in life sciences and favorable funding are key drivers of the Italian market 164
TABLE 128 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 164
TABLE 129 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 130 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 131 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 165
TABLE 132 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 166
TABLE 133 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 166
TABLE 134 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 166
TABLE 135 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167
TABLE 136 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.3.5 SPAIN 167
10.3.5.1 A favorable scenario for research initiatives drives the market in Spain 167
TABLE 137 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 168
TABLE 138 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 139 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 140 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 169
TABLE 141 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 169
TABLE 142 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 169
TABLE 143 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 170
TABLE 144 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170
TABLE 145 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
10.3.6 REST OF EUROPE 171
TABLE 146 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 171
TABLE 147 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 148 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 149 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 172
TABLE 150 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 173
TABLE 151 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 173
TABLE 152 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 173
TABLE 153 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 174
TABLE 154 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 174
10.4 ASIA PACIFIC 174
FIGURE 29 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 175
TABLE 155 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 156 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 176
TABLE 157 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 158 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 177
TABLE 160 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 177
TABLE 161 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 178
TABLE 162 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 178
TABLE 163 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 178
TABLE 164 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 179
10.4.1 JAPAN 179
10.4.1.1 Japan dominates the Asia Pacific market 179
TABLE 165 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 180
TABLE 166 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 167 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 168 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 181
TABLE 169 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 181
TABLE 170 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 181
TABLE 171 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182
TABLE 172 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 182
TABLE 173 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 182
10.4.2 CHINA 183
10.4.2.1 China is the fastest-growing segment of the overall market 183
TABLE 174 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 184
TABLE 175 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 176 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 177 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 185
TABLE 178 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 185
TABLE 179 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 185
TABLE 180 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 186
TABLE 181 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 186
TABLE 182 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 186
10.4.3 INDIA 187
10.4.3.1 Strong economic growth and rising demand for pharmaceuticals are key market drivers in India 187
TABLE 183 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 184 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 185 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 186 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 188
TABLE 187 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 189
TABLE 188 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 189
TABLE 189 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 189
TABLE 190 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190
TABLE 191 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 190
10.4.4 REST OF ASIA PACIFIC 190
TABLE 192 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 191
TABLE 193 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 194 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 195 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 192
TABLE 196 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 192
TABLE 197 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 193
TABLE 198 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 193
TABLE 199 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 193
TABLE 200 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 194
10.5 LATIN AMERICA 194
10.5.1 BRAZIL AND MEXICO TO GROW AT HIGH RATES IN THE LATAM MARKET 194
TABLE 201 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 195
TABLE 202 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 204 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 196
TABLE 205 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 196
TABLE 206 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 196
TABLE 207 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 197
TABLE 208 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 197
TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 197
10.6 MIDDLE EAST AND AFRICA 198
10.6.1 MEA HOLDS THE SMALLEST SHARE OF THE MARKET BUT IS EXPECTED TO PROVIDE STRONG GROWTH OPPORTUNITIES 198
TABLE 210 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 198
TABLE 211 MEA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 212 MEA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 213 MEA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION) 199
TABLE 214 MEA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION) 200
TABLE 215 MEA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION) 200
TABLE 216 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 200
TABLE 217 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 201
TABLE 218 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 201
11 COMPETITIVE LANDSCAPE 202
11.1 OVERVIEW 202
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 203
FIGURE 30 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET 203
11.3 RESEARCH ANTIBODIES MARKET SHARE ANALYSIS 204
FIGURE 31 GLOBAL RESEARCH ANTIBODIES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 204
11.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 206
FIGURE 32 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET, 2019–2021 206
11.5 COMPANY EVALUATION QUADRANT 206
11.5.1 STARS 206
11.5.2 EMERGING LEADERS 206
11.5.3 PERVASIVE PLAYERS 207
11.5.4 PARTICIPANTS 207
FIGURE 33 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT, 2021 207
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 208
11.6.1 PROGRESSIVE COMPANIES 208
11.6.2 STARTING BLOCKS 208
11.6.3 RESPONSIVE COMPANIES 208
11.6.4 DYNAMIC COMPANIES 208
FIGURE 34 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021 209
11.7 COMPANY FOOTPRINT ANALYSIS 210
11.7.1 COMPANY PRODUCT FOOTPRINT 210
TABLE 219 COMPANY PRODUCT FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021) 210
11.7.2 COMPANY REGIONAL FOOTPRINT 211
TABLE 220 COMPANY REGIONAL FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021) 211
11.8 COMPETITIVE SITUATION AND TRENDS 212
TABLE 221 PRODUCT LAUNCHES 212
TABLE 222 DEALS 212
TABLE 223 OTHER DEVELOPMENTS 213

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のバイオ薬物分野での最新刊レポート

本レポートと同じKEY WORD（cytometry）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21　10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.